Press Releases Investors & News / Press Releases Year None202620252024202320222021202020192018201720162015201420132012201120102009 02/24/26 Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March 02/10/26 Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update 02/02/26 Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer 01/27/26 Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026 01/11/26 Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 01/07/26 Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer 01/06/26 Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 Receive Email Alerts Sign up to receive email alerts whenever Exelixis, Inc. posts new information to the site. Just enter your email address and click Submit. Required fields denoted by an asterisk (). Alert type Exelixis SEC Alert Exelixis End-of-Day SEC Alert Exelixis Calendar Alert Exelixis News Alert Exelixis Report Alert Email Leave this field blank Shareholder Tools Information Request Print Page RSS
Year None202620252024202320222021202020192018201720162015201420132012201120102009 02/24/26 Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March 02/10/26 Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update 02/02/26 Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer 01/27/26 Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026 01/11/26 Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 01/07/26 Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer 01/06/26 Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
02/10/26 Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
02/02/26 Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
01/27/26 Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
01/11/26 Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
01/07/26 Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
